Fast Market Research

New Market Study, "Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2015", Has Been Published

Fast Market Research announces the availability of the new Global Markets Direct report, "Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2015", on their comprehensive research portal


Boston, MA -- (SBWIRE) -- 02/15/2016 -- Global Markets Direct's, 'Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2015', provides an overview of the Multiple Myeloma (Kahler Disease)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Multiple Myeloma (Kahler Disease) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Get More Details on this Report and a Full Table of Contents at Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2015

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Report Scope

-The report provides a snapshot of the global therapeutic landscape of Multiple Myeloma (Kahler Disease)
-The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
-The report reviews key players involved in the therapeutics development for Multiple Myeloma (Kahler Disease) and enlists all their major and minor projects
-The report summarizes all the dormant and discontinued pipeline projects
-A review of the Multiple Myeloma (Kahler Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
-Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
-A detailed assessment of monotherapy and combination therapy pipeline projects
-Coverage of the Multiple Myeloma (Kahler Disease) pipeline on the basis of target, MoA, route of administration and molecule type
-Latest news and deals relating related to pipeline products

Reasons to Get this Report

-Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
-Develop strategic initiatives by understanding the focus areas of leading companies
-Identify and understand important and diverse types of therapeutics under development for Multiple Myeloma (Kahler Disease)
-Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
-Devise corrective measures for pipeline projects by understanding Multiple Myeloma (Kahler Disease) pipeline depth and focus of Indication therapeutics
-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
-Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned in this Report: 4SC AG, AB Science SA, AbbVie Inc., Ablynx NV, Acceleron Pharma, Inc., Acetylon Pharmaceuticals, Inc., Actinium Pharmaceuticals, Inc., Adaptimmune Limited, Advancell, Affimed Therapeutics AG, Altor BioScience Corporation, Amgen Inc., Anthera Pharmaceuticals, Inc., APIM Therapeutics AS, APO-T B.V., Arcarios BV, Arno Therapeutics, Inc., Array BioPharma Inc., Arvinas, Inc., Astellas Pharma Inc., Astex Pharmaceuticals, Inc., Atara Biotherapeutics, Inc., Aurigene Discovery Technologies Limited, AvidBiotics Corp., Axelar AB, Bayer AG, Bellicum Pharmaceuticals, Inc., BioInvent International AB, BioLineRx, Ltd., Biotest AG, Bluebird bio, Inc., Boehringer Ingelheim GmbH, Boston Biomedical, Inc., Bristol-Myers Squibb Company, Calithera Biosciences, Inc., Celgene Corporation, Cellectar Biosciences, Inc., Cellectis S.A., Cellerant Therapeutics, Inc., Celleron Therapeutics Limited, Celyad SA, ChemoCentryx, Inc., Chong Kun Dang Pharmaceutical Corp., Cleave Biosciences, Compugen Ltd., Constellation Pharmaceuticals, Inc., ConverGene, LLC, Curis, Inc., Cyclacel Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited, DARA BioSciences, Inc., DC Prime B.V., Dicerna Pharmaceuticals, Inc., Eli Lilly and Company, Enceladus Pharmaceuticals BV, Exelixis, Inc., F. Hoffmann-La Roche Ltd., Fortress Biotech, Inc., Gamida Cell Ltd., Genenta Science s.r.l., GlaxoSmithKline Plc, Gliknik, Inc., Hutchison MediPharma Limited, IGF Oncology, LLC., Immunocore Limited, Immunomedics, Inc., Immunomic Therapeutics, Inc., Incyte Corporation, Inflection Biosciences Limited, Inventiva SAS, Jasco Pharmaceuticals, LLC., Johnson & Johnson, JW Pharmaceutical Corporation, KaloBios Pharmaceuticals, Inc., Kancer Limited, Kancera AB, Karyopharm Therapeutics, Inc., Kezar Life Sciences, Inc., MandalMed, Inc., MedImmune, LLC, Medivation, Inc., Merck & Co., Inc., Merus B.V., Millennium Pharmaceuticals, Inc., Mirna Therapeutics, Inc., Modulation Therapeutics, Inc., Molecular Templates Inc., MolMed S.p.A., MorphoSys AG, NantKwest, Inc., Nippon Kayaku Co., Ltd., Nordic Nanovector ASA, Novartis AG, Noxxon Pharma AG, Oncolytics Biotech Inc., Onconova Therapeutics, Inc., OncoPep Inc., Oncopeptides AB, Ono Pharmaceutical Co., Ltd., Onyx Pharmaceuticals, Inc., OXIS International, Inc., Panacela Labs, Inc., Patrys Limited, Peptinov SAS, Pfizer Inc., Pharma Mar, S.A., Phylogica Limited, Polyphor Ltd., Pono Pharma, Prescient Therapeutics Limited, Progenra, Inc., ProMIS Neurosciences Inc., Quest PharmaTech Inc., Rhizen Pharmaceuticals S.A., Sanofi, Selexys Pharmaceuticals Corporation, Sellas Inc., Selvita SA, Senhwa Biosciences, Inc., Sigma-Tau S.p.A., Sorrento Therapeutics, Inc., Spectrum Pharmaceuticals, Inc., Sphaera Pharma Pvt. Ltd., Stemline Therapeutics, Inc., Sumitomo Dainippon Pharma Co., Ltd., Synta Pharmaceuticals Corp., Taiho Pharmaceutical Co., Ltd., Targazyme, Inc., Teva Pharmaceutical Industries Limited, TG Therapeutics, Inc., Theravectys SA, Threshold Pharmaceuticals, Inc., Tragara Pharmaceuticals, Inc., Transgene Biotek Limited, Vaccibody AS, Vaxil Bio Therapeutics Ltd., Verastem, Inc., Vichem Chemie Research Ltd., Virocan Therapeutics Private Limited, Vivolux AB, XTL Biopharmaceuticals Ltd., Zyngenia, Inc.

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

Browse all Drug Pipeline research reports at Fast Market Research

You may also be interested in these related reports:

-Refractory Multiple Myeloma - Pipeline Review, H2 2015
-Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2015
-Multiple Sclerosis - Pipeline Review, H2 2015
-Alzheimer's Disease - Pipeline Review, H2 2015
-Parkinson's Disease - Pipeline Review, H2 2015